Navidea Biopharmaceuticals, Inc. NAVB, a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, announced today that it
has priced an underwritten sale of common stock in a transaction involving
J.P. Morgan Asset Management and one other institutional investor. Both of
these investors also participated in a similar transaction in early February.
In the offering, 2,100,000 shares were sold in an at-market transaction for a
price of $2.43 per share for gross proceeds of approximately $5.1 million. The
net proceeds of the financing will be used to fund Navidea's ongoing
operations. The sale is expected to close on or about April 29, 2013, subject
to the satisfaction of customary closing conditions.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in